U.S. FDA Accepts Sandoz Applications for Proposed In-house Development of Generic Tirzepatide GLP-1s
June 29, 2026
June 29, 2026
BASEL, Switzerland, June 29 -- Sandoz, a company that say it focuses on generic pharmaceuticals and biosimilars, issued the following news release:
* * *
US FDA accepts Sandoz applications for proposed in-house development of generic tirzepatide GLP-1s
* Sandoz received US FDA file acceptances for generic tirzepatide autoinjector applications
* Proposed generic tirzepatide was developed in-house by Sandoz
* Applications address sam . . .
* * *
US FDA accepts Sandoz applications for proposed in-house development of generic tirzepatide GLP-1s
* Sandoz received US FDA file acceptances for generic tirzepatide autoinjector applications
* Proposed generic tirzepatide was developed in-house by Sandoz
* Applications address sam . . .